Dupilumab was the first FDA-approved biologic for eosinophilic esophagitis, and in combination with omalizumab, it has been investigated for blocking both IgE and IL-4/IL-13 and is also being investigated as both monotherapy and as an adjunct with OIT for food allergy [130,131,132]. The gene discussed is IL13; the disease is food allergy.